![Dirk Pollet](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dirk Pollet
Amministratore Delegato presso Enzyre BV
Posizioni attive di Dirk Pollet
Società | Posizione | Inizio | Fine |
---|---|---|---|
Enzyre BV
![]() Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Amministratore Delegato | 30/04/2019 | - |
Cergentis BV
![]() Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Dirk Pollet
Precedenti posizioni note di Dirk Pollet
Società | Posizione | Inizio | Fine |
---|---|---|---|
Multiplicom NV
![]() Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Direttore/Membro del Consiglio | 15/04/2011 | 01/03/2017 |
Amministratore Delegato | 03/05/2011 | 01/03/2017 | |
CELLECTIS S.A. | Corporate Officer/Principal | 28/05/2010 | 01/06/2011 |
Galapagos Genomics NV
![]() Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | 01/09/2000 | 02/05/2008 |
Formazione di Dirk Pollet
University of Antwerp | Doctorate Degree |
Statistiche
Distribuzione geografica
Belgio | 4 |
Paesi Bassi | 3 |
Francia | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Aziende private | 4 |
---|---|
Galapagos Genomics NV
![]() Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Multiplicom NV
![]() Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Health Technology |
Enzyre BV
![]() Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Technology Services |
Cergentis BV
![]() Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Commercial Services |
- Borsa valori
- Insiders
- Dirk Pollet
- Esperienza